VivoSeq
Oncology

Renal Pelvis and Ureter Urothelial Carcinoma

9

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Renal Pelvis and Ureter Urothelial Carcinoma is an early-stage landscape with 9 programs across 6 companies. The most active players are Gynecologic Oncology Group, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

2 programs

PreclinicalM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

PreclinicalAstraZeneca logo

AstraZeneca

1 program

PreclinicalAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

PreclinicalAmgen logo

Amgen

1 program

PreclinicalE

Eastern Cooperative Oncology Group

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

6 of 8 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody113%Protein / enzyme113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 89% of 9 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Prospective Clinical Assessment of Office-Based Ureteroscopy for Upper Tract Urothelial Carcinoma Utilizing a 6.3 French Single Use Digital Flexible Ureteroscope
Recruiting·UUniversity of Michigan Rogel Cancer Center·Preclinical·NCT07630155·10 enrolled
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT04628767·131 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)